home.aspx
 
EVENTS

The Digital Pharma Advances
THE DIGITAL PHARMA ADVANCES
January 29-29, 2020
Powerfully Target & Engage HCPs & Patients & Deliver Real-World Results With Integrated, Innovative Digital Strategies.Customer-Centric, Value-Adding, Multi-Channel Digital Pharma Marketing Strategies.

4th Annual Microbiome Movement, Drug Development, Europe
4TH ANNUAL MICROBIOME MOVEMENT, DRUG DEVELOPMENT, EUROPE
February 04-05, 2020
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effecti...

Biorasi

SHARESHARESHARE
Biorasi is a contract research organization (CRO) widely recognized for delivering success in complex clinical trials. This is possible through TALOS™, an innovative operating model that unifies systems and teams with a powerful project
SHARESHARESHARE

RELATED NEWS


New research published in the journal Pediatric Blood and Cancer shows how early cancer screening and surveillance in patients with Li-Fraumeni Syndrome (LFS) results in additional years of life and is cost effective for third-party payers. LFS is an inherited genetic condition that greatly increases the risk of developing several types of cancer. People diagnosed with LFS have a one in two chance of developing cancer by 30, and a nearly 100 percent risk of developing cancer in their lifetime, c...

READ MORE

National Safety Council analysis reveals trends that worsen the odds of dying accidentally. For the first time in U.S. history, a person is more likely to die from an accidental opioid overdose than from a motor vehicle crash, according to National Safety Council analysis. The odds of dying accidentally from an opioid overdose have risen to one in 96, eclipsing the odds of dying in a motor vehicle crash (one in 103). The National Safety Council unveiled the analysis on Injury Facts – the d...

READ MORE

Chatter at an early morning session on the third day of the 43rd annual meeting in Washington, D.C., was largely focused on the state of healthcare....

READ MORE

Research and Markets has announced the addition of the "Global Pharmaceutical Contract Manufacturing Market 2016-2020" report to their offering. The global pharmaceutical contract manufacturing market to grow at a CAGR of 6.91% during the period 2016-2020. The report covers the present scenario and the growth prospects of the global pharmaceutical contract manufacturing market for 2016-2020. To calculate the market size, the report considers the revenue generated from various pharmaceutical dru...
GLOBENEWSWIRE.COM
READ MORE

A clinical trial testing AstraZeneca’s experimental drug AZD1775, an inhibitor of the cell cycle regulating protein WEE1, in patients with head and neck cancer has now launched in the UK....

READ MORE

It doesn't often happen that army generals switch sides in the middle of a war, but when cancer's attack is underway, it may even cause a gene that acts as the body's master defender to change allegiance. As reported recently in the Proceedings of the National Academy of Sciences (PNAS), researchers at the Weizmann Institute of Science have discovered that the betrayal of this gene can occur in more ways than previously appreciated. All cells carry this gene, known as p53. This gene ...
WEIZMANN INSTITUTE OF SCIENCE
READ MORE

EVENTS

The Digital Pharma Advances
THE DIGITAL PHARMA ADVANCES
January 29-29, 2020
Powerfully Target & Engage HCPs & Patients & Deliver Real-World Results With Integrated, Innovative Digital Strategies.Customer-Centric, Value-Adding, Multi-Channel Digital Pharma Marketing Strategies.

4th Annual Microbiome Movement, Drug Development, Europe
4TH ANNUAL MICROBIOME MOVEMENT, DRUG DEVELOPMENT, EUROPE
February 04-05, 2020
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effecti...